A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

Por Holen, Kyle D., Belani, Chandra P., Wilding, George, Ramalingam, Suresh, Volkman, Jennifer L., Ramanathan, Ramesh K., Vasist, Lakshmi S., Bowen, Carolyn J., Hodge, Jeffrey P., Dar, Mohammed M., Ho, Peter T. C.
Publicado em 2010

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors

Por Heath, Elisabeth I., Infante, Jeffrey, Lewis, Lionel D., Luu, Thehang, Stephenson, Joe, Tan, Antoinette R., Kasubhai, Saifuddin, LoRusso, Patricia, Ma, Bo, Suttle, A. Benjamin, Kleha, Joseph F., Ball, Howard A., Dar, Mohammed M.
Publicado em 2013

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

Por Tan, Antoinette R., Dowlati, Afshin, Jones, Suzanne F., Infante, Jeffrey R., Nishioka, Jennifer, Fang, Lei, Hodge, Jeffrey P., Gainer, Shelby D., Arumugham, Thangam, Suttle, A. Benjamin, Dar, Mohammed M., Lager, Joanne J., Burris, Howard A.
Publicado em 2010

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function

Por Devriese, Lot A, Witteveen, Petronella (Els) O, Mergui-Roelvink, Marja, Smith, Deborah A, Lewis, Lionel D, Mendelson, David S, Bang, Yung-Jue, Chung, Hyun Choel, Dar, Mohammed M, Huitema, Alwin D R, Beijnen, Jos H, Voest, Emile E, Schellens, Jan H M
Publicado no Br J Clin Pharmacol (2015)